Document is current
Any future updates will be listed below
-
Authors
Sherwood, Matthew https://orcid.org/0000-0002-1912-9758
Mitsugi, Thiago G. https://orcid.org/0000-0001-5940-194X
Kaid, Carolini https://orcid.org/0000-0002-1852-6997
Coke, Brandon https://orcid.org/0000-0002-0847-6885
Zatz, Mayana https://orcid.org/0000-0003-3970-8025
Maringer, Kevin https://orcid.org/0000-0003-0977-8807
Okamoto, Oswaldo K. https://orcid.org/0000-0002-8528-6225
Ewing, Rob M. https://orcid.org/0000-0001-6510-4001
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/S01411X/1, MR/S01411X/1)
Little Princess Trust
Wessex Medical Research
Rosetrees Trust
BBSRC (BBS/E/PI/230001A)
Biotechnology and Biological Sciences Research Council (BBS/E/PI/23NB0003)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/08028-1)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (302736/2022-0)
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 7 April 2025
First Online: 16 April 2025
Declarations
:
: CK is CEO and co-founder at Vyro biotherapeuticsOKO is an Advisor at Vyro biotherapeuticsAll other authors declare no competing interests.
